{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:55:19Z","timestamp":1794952519516,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Psychiatry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/s2215-0366(25)00296-2","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:47:10Z","timestamp":1762962430000},"page":"906-920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials"],"prefix":"10.1016","volume":"12","author":[{"given":"Richard S E","family":"Keefe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Falkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Medalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomiki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Blahova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Bichard-Sall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Gruenenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Groeschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"von der Goltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2215-0366(25)00296-2_bib1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/wps.20624","article-title":"Nonsocial and social cognition in schizophrenia: current evidence and future directions","volume":"18","author":"Green","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2011.10.015","article-title":"The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates","volume":"134","author":"August","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/S2215-0366(25)00296-2_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.schres.2017.10.018","article-title":"Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults","volume":"195","author":"DeRosse","year":"2018","journal-title":"Schizophr Res"},{"key":"10.1016\/S2215-0366(25)00296-2_bib5","article-title":"Healthcare resource utilization and quality of life by cognitive impairment in patients with schizophrenia","volume":"28","author":"Kadakia","year":"2021","journal-title":"Schizophr Res Cogn"},{"key":"10.1016\/S2215-0366(25)00296-2_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2010.11.008","article-title":"The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study","volume":"126","author":"Kern","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/S2215-0366(25)00296-2_bib7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/schbul\/sbae075","article-title":"Thinking about the future of cognitive remediation therapy revisited: what is left to solve before patients have access?","volume":"50","author":"Wykes","year":"2024","journal-title":"Schizophr Bull"},{"key":"10.1016\/S2215-0366(25)00296-2_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2017.08.005","article-title":"Compensatory cognitive training for people with severe mental illnesses in supported employment: a randomized controlled trial","volume":"203","author":"Twamley","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1016\/S2215-0366(25)00296-2_bib9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamapsychiatry.2021.0620","article-title":"Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized clinical trials","volume":"78","author":"Vita","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41380-022-01727-z","article-title":"Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jpsychires.2025.02.024","article-title":"Exercise as a transdiagnostic intervention for improving mental health: an umbrella review","volume":"184","author":"Solmi","year":"2025","journal-title":"J Psychiatr Res"},{"key":"10.1016\/S2215-0366(25)00296-2_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/S2215-0366(25)00296-2_bib13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/archpsyc.1997.01830220085012","article-title":"Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy","volume":"54","author":"Bartha","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/S2215-0366(25)00296-2_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib16","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1176\/appi.ajp.159.11.1944","article-title":"Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers","volume":"159","author":"Th\u00e9berge","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.742058","article-title":"Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia","volume":"12","author":"Pei","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1174738","article-title":"N-methyl-D-aspartate receptor hypofunction as a potential contributor to the progression and manifestation of many neurological disorders","volume":"16","author":"Dong","year":"2023","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/S2215-0366(25)00296-2_bib19","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.biopsych.2017.01.004","article-title":"Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: a translational and computational neuroscience perspective","volume":"81","author":"Krystal","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib20","doi-asserted-by":"crossref","first-page":"15730","DOI":"10.1073\/pnas.95.26.15730","article-title":"Modulation of N-methyl-D-aspartate receptor function by glycine transport","volume":"95","author":"Bergeron","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S2215-0366(25)00296-2_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145703003900","article-title":"Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms","volume":"7","author":"Sumiyoshi","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/S2215-0366(25)00296-2_bib22","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"Bugarski-Kirola","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","article-title":"Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia","volume":"273","author":"Rosenbrock","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/S2215-0366(25)00296-2_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.121.001071","article-title":"Effects of the glycine transporter-1 inhibitor iclepertin (BI 425809) on sensory processing, neural network function, and cognition in animal models related to schizophrenia","volume":"382","author":"Rosenbrock","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S2215-0366(25)00296-2_bib27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cts.12578","article-title":"Evaluation of pharmacokinetics and pharmacodynamics of BI 425809, a novel GlyT1 inhibitor: translational studies","volume":"11","author":"Rosenbrock","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/S2215-0366(25)00296-2_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13318-017-0440-z","article-title":"Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study","volume":"43","author":"Moschetti","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/S2215-0366(25)00296-2_bib29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40261-018-0660-2","article-title":"Multiple rising doses of oral BI 425809, a GlyT1 inhibitor, in young and elderly healthy volunteers: a randomised, double-blind, phase I study investigating safety and pharmacokinetics","volume":"38","author":"Moschetti","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/S2215-0366(25)00296-2_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.clinthera.2019.03.014","article-title":"Pharmacokinetics of single doses of BI 425809 in healthy Chinese and Japanese subjects: a randomized study","volume":"41","author":"Tsuda","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/S2215-0366(25)00296-2_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1176\/appi.ajp.163.3.426","article-title":"The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity","volume":"163","author":"Keefe","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2024.11.006","article-title":"AI-based medication adherence prediction in patients with schizophrenia and attenuated psychotic disorders","volume":"275","author":"Zhu","year":"2025","journal-title":"Schizophr Res"},{"key":"10.1016\/S2215-0366(25)00296-2_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2010.09.015","article-title":"Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial","volume":"125","author":"Keefe","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/S2215-0366(25)00296-2_bib35","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1017\/S135561771100018X","article-title":"Tower of London versus real life analogue planning in schizophrenia with disorganization and psychomotor poverty symptoms","volume":"17","author":"Greenwood","year":"2011","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/S2215-0366(25)00296-2_bib36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamapsychiatry.2017.1574","article-title":"Placebo response and practice effects in schizophrenia cognition trials","volume":"74","author":"Keefe","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41398-022-02096-5","article-title":"Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: a phase II substudy of patients treated with iclepertin (BI 425809)","volume":"12","author":"Schultheis","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib38","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/npp.2014.4","article-title":"Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates","volume":"39","author":"Castner","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S2215-0366(25)00296-2_bib39","series-title":"Neurocrine Biosciences provides update on ERUDITE phase 2 data for luvadaxistat in adults with cognitive impairment associated with schizophrenia","year":"2024"},{"key":"10.1016\/S2215-0366(25)00296-2_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.schres.2024.06.017","article-title":"INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia","volume":"270","author":"Murthy","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/S2215-0366(25)00296-2_bib42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.biopsych.2017.12.019","article-title":"Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor PF-03463275 in healthy and schizophrenia subjects","volume":"84","author":"D'Souza","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/S2215-0366(25)00296-2_bib43","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/npp.2011.295","article-title":"Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence","volume":"37","author":"D'Souza","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S2215-0366(25)00296-2_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116376","article-title":"Passing the torch: the ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia","volume":"228","author":"Coyle","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S2215-0366(25)00296-2_bib45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"key":"10.1016\/S2215-0366(25)00296-2_bib46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1527-3458.1995.tb00285.x","article-title":"Glycine site agonists of the NMDA receptor: a review","volume":"1","author":"D'Souza","year":"1995","journal-title":"CNS Drug Rev"},{"key":"10.1016\/S2215-0366(25)00296-2_bib47","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1523\/JNEUROSCI.3836-12.2013","article-title":"Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity","volume":"33","author":"Rosenberg","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/S2215-0366(25)00296-2_bib48","article-title":"Glycine-induced NMDA receptor internalization provides neuroprotection and preserves vasculature following ischemic stroke","volume":"25","author":"Cappelli","year":"2021","journal-title":"iScience"},{"key":"10.1016\/S2215-0366(25)00296-2_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/schbul\/sbae191","article-title":"Commentary","volume":"51","author":"Keefe","year":"2025","journal-title":"Schizophr Bull"},{"key":"10.1016\/S2215-0366(25)00296-2_bib50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/schbul\/sbae151","article-title":"Towards enhancing drug development methodology to treat cognitive impairment associated with schizophrenia and other neuropsychiatric conditions: insights from 2 decades of clinical trials","volume":"51","author":"Horan","year":"2025","journal-title":"Schizophr Bull"}],"container-title":["The Lancet Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036625002962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036625002962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:09:36Z","timestamp":1769026176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215036625002962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2215036625002962"],"URL":"https:\/\/doi.org\/10.1016\/s2215-0366(25)00296-2","relation":{},"ISSN":["2215-0366"],"issn-type":[{"value":"2215-0366","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2215-0366(25)00296-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}